Trial Profile
A retrospective case-control study assessing the background incidence rate of one Adverse Event in individuals with Alzheimer's disease (AD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Aug 2020
Price :
$35
*
At a glance
- Drugs Crenezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 27 Aug 2020 New trial record
- 31 Jul 2020 Results presented at the Alzheimer's Association International Conference 2020